Latest Stent Stories

VANCOUVER, Nov. 16, 2012 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced that its partner Cook Medical, Inc. ("Cook") received approval on November 15, 2012 from the U.S. Food and Drug Administration ("FDA") to market and sell the proprietary Zilver® PTX® drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale. Zilver PTX is the first drug-eluting...

SAN DIEGO, Nov. 14, 2012 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that results from the largest study of its kind show that stent procedures guided by intravascular ultrasound (IVUS) resulted in better patient outcomes and fewer complications at 30 days and 12 months compared to procedures...

SINGAPORE, Nov. 7, 2012 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the second quarter of fiscal year 2013 (Q2 FY13) and the fiscal six months ended 30 September 2012 (H1 FY13). Q2 FY13 and Recent Highlights: Total revenue of US$79.8 million, representing 28% year-on-year growth...

DURHAM, N.C., Nov. 6, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the company's surface and polymer modification technology. This intellectual property protection is related to Micell's investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), as well as potential additional biomedical products. The patent rights are assigned to...

TEL AVIV, Israel, November 5, 2012 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPR) announced today that the randomized 432-patient MASTER trial of its embolic protective MGuard stent will be published in the November 6, 2012 print edition of the peer-reviewed Journal of American College of Cardiology, Vol. 60, No. 19. The online version of the paper, authored by Gregg W. Stone, MD and others, appeared a week ago Wednesday (October 24) at:...

BILLERICA, Mass., Nov. 1, 2012 /PRNewswire/ -- SRS Medical announces the acquisition of The Spanner Temporary Prostatic Stent from AbbeyMoor Medical of Parkers Prairie, MN. The Spanner is FDA cleared, CE-marked, has a dedicated CPT code and is protected by patents worldwide. SRS is manufacturing The Spanner in the United States and distributing it worldwide through a hybrid distribution model of employed and brokerage representation. "The Spanner is a synergistic addition to our...

HELMOND, The Netherlands, October 30, 2012 /PRNewswire/ -- Innovator in the treatment of vascular diseases launches non compliant DEB worldwide Blue Medical, the global medical device company and innovator in the treatment of vascular diseases, today announced receiving the CE mark for Protege NC, a non compliant drug eluting balloon. The new device will be launched worldwide. It follows the introduction of Blue Medical's CE marked Drug Eluting Balloon Protege and CoCr...

Nitinol stent performs better than balloon angioplasty alone in treating lesions of the popliteal artery A study found that a nitinol stent performed better than balloon angioplasty alone in treating blockages of the popliteal artery, which runs through the leg behind the knee. Results of the ETAP trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's...

Second generation drug-eluting stents are safe and effective in treatment of left main coronary artery disease A study found that second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions. Results of the ISAR-LEFT MAIN 2 trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting...

Results of the MASTER trial reported at TCT 2012 and published in JACC A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty. Results of the MASTER trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and will appear in...